Compare Ecolab Inc. (ECL) vs Hims and Hers Health Inc (HIMS) Price & Performance

ECL trades at $269.75, down 0.77% on the day, with a bearish technical signal. The stock shows strong fundamentals with 2025 revenue of $16.08B and net income of $2.08B, though recent quarterly EPS results have been mixed. The company recently completed the $4.75B CoolIT acquisition to strengthen its AI cooling portfolio, positioning high-tech as a growth engine. Analyst consensus remains strongly bullish with a $327.43 price target, representing 21% upside potential from current levels.

The outlook is positive given strong analyst support and strategic acquisitions, but risks include execution of the CoolIT integration, rising cost pressures, and mixed quarterly earnings performance. The stock's premium valuation (P/E 36.57) requires sustained earnings growth to justify current levels, making upcoming Q2 2026 results on July 28 critical for near-term direction.

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.